Gene: GPD1L

23171
GPD1-L
glycerol-3-phosphate dehydrogenase 1 like
protein-coding
3p22.3
Ensembl:ENSG00000152642 MIM:611778 Vega:OTTHUMG00000155846 UniprotKB:Q8N335
NG_023375.1
PubMed
0   ANCO-SNPs
AD
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
6.720e-1 (AD)  9.106e-3 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
PIK3CB0.954
COL4A3BP0.951
GLS0.95
HSPA12A0.948
UBE2K0.948
BCAP290.946
NAPB0.945
TRIM370.945
MAPK90.944
ATP6V1C10.944

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.517
OR4F29-0.511
AQP5-0.456
LRAT-0.444
HEY2-0.431
WDR38-0.423
TGIF1-0.415
CSAG1-0.414
EVC2-0.413
FLT3LG-0.408

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0512461-methylanthracene[1-methylanthracene co-treated with fluoranthene] results in decreased expression of GPD1L mRNA28329830
C0303702-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone"2-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone results in decreased expression of GPD1L mRNA"20206263
C5724913-(2-hydroxy-4-(2-methylnonan-2-yl)phenyl)cyclohexan-1-ol3-(2-hydroxy-4-(2-methylnonan-2-yl)phenyl)cyclohexan-1-ol results in increased expression of GPD1L protein26194647
C0284513,4,3',4'-tetrachlorobiphenyl"3,4,3',4'-tetrachlorobiphenyl inhibits the reaction [Dietary Fats results in increased expression of GPD1L mRNA]"19467301
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA"27188386
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of GPD1L mRNA27153756
C068073Am 580Am 580 results in decreased expression of GPD1L mRNA16982809
D017638Asbestos, Crocidolite"Asbestos, Crocidolite results in decreased expression of GPD1L mRNA"25351596
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of GPD1L mRNA20106945
D004958Estradiol[Estradiol co-treated with Progesterone] results in increased expression of GPD1L mRNA20660070
D004958Estradiol[Progesterone co-treated with Estradiol] results in increased expression of GPD1L mRNA17404688
D004958Estradiol[bisphenol A co-treated with Estradiol] results in increased expression of GPD1L mRNA26496021
C006780bisphenol A[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of GPD1L mRNA28628672
C006780bisphenol A[bisphenol A co-treated with Estradiol] results in increased expression of GPD1L mRNA26496021
C006780bisphenol A[bisphenol A co-treated with Testosterone] results in increased expression of GPD1L mRNA26496021
C006780bisphenol Abisphenol A results in increased expression of GPD1L mRNA25181051
C000611646bisphenol F[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of GPD1L mRNA28628672
C584509C646 compoundC646 compound results in increased expression of GPD1L mRNA26191083
D019327Copper SulfateCopper Sulfate results in decreased expression of GPD1L mRNA19549813
D016572CyclosporineCyclosporine results in increased expression of GPD1L mRNA25562108|2798913
D003907DexamethasoneDexamethasone results in increased expression of GPD1L mRNA25047013
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of GPD1L mRNA28628672
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of GPD1L mRNA28628672
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in increased expression of GPD1L mRNA27392435
D002945CisplatinCisplatin results in increased expression of GPD1L mRNA27392435
D004041Dietary Fats"3,4,3',4'-tetrachlorobiphenyl inhibits the reaction [Dietary Fats results in increased expression of GPD1L mRNA]"19467301
D004041Dietary FatsDietary Fats results in decreased expression of GPD1L mRNA25016146
D004041Dietary FatsDietary Fats results in increased expression of GPD1L mRNA19467301
D004147DioxinsDioxins affects the expression of GPD1L mRNA20463971
D004221DisulfiramDisulfiram results in decreased expression of GPD1L mRNA20530235
C118739entinostatentinostat results in increased expression of GPD1L mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA"27188386
C007738fluoranthene[1-methylanthracene co-treated with fluoranthene] results in decreased expression of GPD1L mRNA28329830
D005944GlucosamineGlucosamine results in increased expression of GPD1L mRNA17178593
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of GPD1L mRNA28628672
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of GPD1L mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of GPD1L mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of GPD1L mRNA28628672
C544151jinfukang[Cisplatin co-treated with jinfukang] results in increased expression of GPD1L mRNA27392435
D010100OxygenOxygen deficiency results in decreased expression of GPD1L protein25937538
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA"27188386
C496932panobinostatpanobinostat results in increased expression of GPD1L mRNA26272509
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of GPD1L mRNA26272509
D011374ProgesteroneProgesterone results in increased expression of GPD1L mRNA20631399
D011374Progesterone[Estradiol co-treated with Progesterone] results in increased expression of GPD1L mRNA20660070
D011374Progesterone[Progesterone co-treated with Estradiol] results in increased expression of GPD1L mRNA17404688
D011794QuercetinQuercetin results in decreased expression of GPD1L mRNA21632981
C059514resveratrolresveratrol results in increased expression of GPD1L protein25505154
C089730rosiglitazonerosiglitazone results in decreased expression of GPD1L mRNA16982809
D012822Silicon DioxideSilicon Dioxide results in decreased expression of GPD1L mRNA25351596
D012822Silicon DioxideSilicon Dioxide results in decreased expression of GPD1L mRNA23221170
D013739Testosterone[bisphenol A co-treated with Testosterone] results in increased expression of GPD1L mRNA26496021
C020806tetrabromobisphenol Atetrabromobisphenol A results in decreased expression of GPD1L mRNA27914987
D013893ThiramThiram results in decreased expression of GPD1L mRNA20530235
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA"27188386
C012589trichostatin Atrichostatin A results in increased expression of GPD1L mRNA24935251|2627250
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of GPD1L mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of GPD1L mRNA23179753|2438349
C111237vorinostat"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA"27188386
C111237vorinostatvorinostat results in increased expression of GPD1L mRNA26272509

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004367glycerol-3-phosphate dehydrogenase [NAD+] activity-TAS-  
GO:0017080sodium channel regulator activity-IMP17967977  19666841  
GO:0042803protein homodimerization activity-IEA-  
GO:0044325ion channel binding-IPI19666841  
GO:0051287NAD binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0002027regulation of heart rate-IMP17967977  19666841  
GO:0005975carbohydrate metabolic process-IEA-  
GO:0006654phosphatidic acid biosynthetic process-TAS-  
GO:0006734NADH metabolic process-IEA-  
GO:0010765positive regulation of sodium ion transport-IMP17967977  19666841  19745168  
GO:0019674NAD metabolic process-IMP19745168  
GO:0033137negative regulation of peptidyl-serine phosphorylation-IMP19666841  
GO:0046168glycerol-3-phosphate catabolic process-IEA-  
GO:0055114oxidation-reduction process-IEA-  
GO:0060373regulation of ventricular cardiac muscle cell membrane depolarization-IMP17967977  19666841  
GO:0086005ventricular cardiac muscle cell action potential-IMP17967977  19666841  
GO:0090038negative regulation of protein kinase C signaling-IMP19666841  
GO:2000010positive regulation of protein localization to cell surface-IMP17967977  19666841  
GO:2000649regulation of sodium ion transmembrane transporter activity-IMP17967977  19666841  
GO ID GO Term Qualifier Evidence PubMed
GO:0005829cytosol-TAS-  
GO:0005886plasma membrane-IDA17967977  
GO:0009331glycerol-3-phosphate dehydrogenase complex-IEA-  
GO:0070062extracellular exosome-HDA23533145  
KEGG ID KEGG Term
hsa00564Glycerophospholipid metabolism
Reactome ID Reactome Term Evidence
R-HSA-1430728MetabolismTAS
R-HSA-1483166Synthesis of PATAS
R-HSA-1483206Glycerophospholipid biosynthesisTAS
R-HSA-1483257Phospholipid metabolismTAS
R-HSA-556833Metabolism of lipidsTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
25278008Genome-wide association discoveries of alcohol dependence. (2014 Nov-Dec)Zuo LAm J Addict